Article
Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
BMC cancer - 24 Sept 2011
Borràs Emma, Jurado Ismael, Hernan Imma, Gamundi María José, Dias Miguel, Martí Isabel, Mañé Begoña, Arcusa Angels, Agúndez José A G, Blanca Miguel, Carballo Miguel
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mutated in several types of cancer, affecting the clinical response to EGFR inhibitors. Mutations in the EGFR kinase domain predict sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in lung adenocarcinoma, while activating point mutations in KRAS and BRAF confer resistance to the anti-EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.